Increasing the integration of upstream and downstream processing and moving toward increased automation results in greater optimization of process efficiency - a key goal for biopharmaceutical production.
Securing a partner to serve as an extension of Janssen’s Biotherapeutics Development API-Large Molecule team was essential to reducing both risk and the time needed for delivery of critical clinical supplies.
3D printing allows drug companies to not only boost efficacy and adherence but also contribute to their brand longevity by expanding and capturing market share with other dosage form options.
The properties of the particles that make up a pharmaceutical powder directly affect its behavior, a classic example being that finer particles are usually associated with poor flowability. However, so too do other ‘system’ variables, such as the degree of aeration or consolidation. The analytical toolkit required for the knowledge-led control of formulation properties therefore necessarily extends from particle characterization through to bulk powder testing techniques. Particle characteristics are the levers manipulated to meet performance targets, but bulk powder properties often define some of these targets. Marrying the results from both types of analysis is often the key to efficient progress.
For an industry in which collaborative working is increasingly the norm, turning to external experts for analytical input provides a cost-effective route to the latest instrumentation, robust, precise measurement and reliable data interpretation.
Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
Vaccines are absolutely crucial for maintaining global health, but are a challenge to develop and manufacture. How can businesses ensure profitability while providing low prices for developing countries?
How far have we come in raw material supply management, and what still needs accomplished to ensure the delivery of safe and effective drugs?
Materials science is now helping pharmaceutical companies to standardize and control areas such as drug form and manufacture to deliver new products more quickly and with greater quality.
The ADC field is in a transitional period. Older approaches to conjugate composition and dosing regimens still dominate the ADC clinical pipeline, but preclinical work is driving a rapid evolution in how we strategize to improve efficacy and reduce toxicity towards better therapeutic outcomes. In an indication of future directions for the field, antibody conjugates bearing non-cytotoxic small molecule payloads are being developed to reduce side effects associated with treatment of chronic diseases.
|
|
|
|
|
|
|
|
|